论文部分内容阅读
目的评价新辅助化疗联合新辅助内分泌治疗对绝经后、ER(+)乳腺癌的近期疗效及与受体的相关性。方法 40例绝经后乳腺癌,给予FEC方案新辅助化疗联合速莱方案新辅助内分泌治疗,治疗时间8周。结果 40例患者,完全缓解4例(10%),部分缓解14例(35%),轻度缓解21例(52.5%),无变化1例(2.5%),进展0例(0%)。其中ER和PR双阳性的为27例,完全缓解3例(11.1%),部分缓解11例(40.7%),轻度缓解13例(48.1%);单独ER阳性的13例,完全缓解1例(7.7%),部分缓解3例(23.1%),轻度缓解8例(61.5%),无变化1例(7.7%);两组疗效比较,差异有统计学意义(P<0.01)。40例患者经8周新辅助化疗联合新辅助内分泌治疗后,均接受手术治疗,其中5例行保乳手术,31例行乳腺癌改良根治术,4例行经典根治术治疗,术后继续相关辅助治疗。结论绝经后、ER(+)乳腺癌患者采用FEC方案新辅助化疗联合速莱方案新辅助内分泌治疗有效、安全、可靠,为缩小手术切除术式创造了条件。
Objective To evaluate the short-term effect of neoadjuvant chemotherapy combined with neoadjuvant endocrine therapy on postmenopausal and ER (+) breast cancer and its correlation with the receptor. Methods 40 cases of postmenopausal breast cancer were given neoadjuvant endocrine therapy with FEC regimen neoadjuvant chemotherapy combined with Suolai regimen for 8 weeks. Results In 40 cases, complete remission was achieved in 4 cases (10%), partial remission in 14 cases (35%), mild remission in 21 cases (52.5%), no change in 1 case (2.5%) and progression in 0 case (0%). There were 27 positive cases of ER and PR, 3 complete remission (11.1%), partial remission in 11 cases (40.7%) and mild remission in 13 cases (48.1%); (7.7%), partial remission in 3 cases (23.1%), mild remission in 8 cases (61.5%) and no change in 1 case (7.7%). There was significant difference between the two groups (P <0.01). Forty patients were treated by neoadjuvant chemotherapy and neoadjuvant endocrine therapy for 8 weeks. Five patients underwent breast conserving surgery, 31 underwent modified radical mastectomy and 4 underwent classical radical mastectomy, Assisted treatment. Conclusions Postmenopausal, ER (+) breast cancer patients with FEC regimen neoadjuvant chemotherapy combined with Supravenal regimen neoadjuvant endocrine therapy is effective, safe and reliable, and to create the conditions for the reduction of surgical resection.